Who is sponsoring NCT04270474?

NCT04270474 is sponsored by Indiana University.

What drugs are being tested in NCT04270474?

Interventions in NCT04270474: Deprescribing of target anticholinergics, Usual Care.

What condition does NCT04270474 study?

NCT04270474 studies Dementia, Alzheimer Disease, Late Onset.

Is NCT04270474 still recruiting?

NCT04270474 is currently active, enrolled. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT04270474: R2D2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reducing Risk of Dementia Through Deprescribing

Active, enrolled NA Last updated 15 April 2026

What this trial tests

NA trial testing Deprescribing of target anticholinergics in Dementia in 344 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

20 July 2020

Primary endpoint
30 July 2026

30 July 2026

Quick facts

Lead sponsor	Indiana University
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	344
Start date	20 July 2020
Primary completion	30 July 2026
Estimated completion	30 July 2026
Sites	2 locations across United States

Drugs / interventions tested

Deprescribing of target anticholinergics
Usual Care

Conditions studied

Dementia — all drugs for Dementia →
Alzheimer Disease, Late Onset — all drugs for Alzheimer Disease, Late Onset →

Sponsor

Indiana University

Who can join

65 and older, any sex, with Dementia or Alzheimer Disease, Late Onset. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Deprescribing anticholinergics in primary care older adults: Experience from two models and impact on a continuous measure of exposure.
Campbell NL, Pitts C, Corvari C, Kaehr E, et al · · 2022 · cited 7× · PMID 36620097 · DOI 10.1002/jac5.1682
Deprescribing anticholinergics to preserve brain health: reducing the risk of dementia through deprescribing (R2D2): study protocol for a randomized clinical trial.
Campbell NL, Holden RJ, Gao S, Unverzagt FW, et al · · 2024 · PMID 39578926 · DOI 10.1186/s13063-024-08618-4
Deprescribing Anticholinergics to Preserve Brain Health: Reducing the Risk of Dementia through Deprescribing (R2D2): Study Protocol for a Randomized Clinical Trial
Campbell NL, Holden RJ, Gao S, Unverzagt FW, et al · · 2024 · DOI 10.21203/rs.3.rs-4682599/v1
Full GSA 2022 Abstract Book PDF.
· 2022 · PMID 36570860 · DOI 10.1093/geroni/igac059
DIURNAL CORTISOL SECRETION AND SELF-REPORTED AND CAREGIVER-REPORTED QUALITY OF LIFE IN PEOPLE LIVING WITH DEMENTIA
· 2022
ANNUALIZED AND CUMULATIVE MEASURES OF ANTICHOLINERGIC EXPOSURE FOR RESEARCH AND CLINICAL APPLICATIONS
· 2022
ADAPTING STAKEHOLDER WALKABILITY/WHEELABILITY AUDIT TOOL IN NEIGHBORHOOD FOR SENSORY AND COGNITIVE DISABILITIES
· 2022

Verify or expand the search:

Other recruiting trials for Dementia

Currently open trials in the same condition.

NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT06088810 — The Impact of Music Intervention on Sleep · NA · recruiting
NCT07482800 — Dementia in Fiction and Clinical Narratives · recruiting
NCT07392944 — Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Home · NA · recruiting

Other Indiana University trials

Trials by the same sponsor.

NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04270474 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indiana University
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04270474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing